{"commentary":{"count":65,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":35,"podcast":24,"x_thread":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02000622\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"OlympiAD","nct_id":"NCT02000622","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=olympiad-nct02000622. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"OlympiAD","arms":[{"description":"Olaparib tablet 300mg bd po","label":"Olaparib","type":"EXPERIMENTAL"},{"description":"Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21","label":"Physician's choice chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Myriad Genetic Laboratories, Inc.","Merck Sharp & Dohme LLC"],"completion_date":{"date":"2025-12-23","type":"ACTUAL"},"conditions":["Breast Cancer Metastatic","BRCA 1 Gene Mutation","BRCA 2 Gene Mutation"],"enrollment":{"count":302,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Olaparib","type":"DRUG"},{"name":"Physician's choice chemotherapy","type":"DRUG"}],"last_update":"2026-02-13","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2016-12-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)","timeFrame":"Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months."}],"references":[{"citation":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4.","pmid":"28578601","type":"DERIVED"}],"start_date":{"date":"2014-03-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","url":"https://clinicaltrials.gov/study/NCT02000622"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/olympiad-nct02000622"}